167 related articles for article (PubMed ID: 25600969)
1. A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy.
Pan D; Kim B; Hu G; Gupta DS; Senpan A; Yang X; Schmieder A; Swain C; Wickline SA; Tomasson MH; Lanza GM
Nanomedicine (Lond); 2015 Jan; 10(2):241-51. PubMed ID: 25600969
[TBL] [Abstract][Full Text] [Related]
2. Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma.
Soodgupta D; Pan D; Cui G; Senpan A; Yang X; Lu L; Weilbaecher KN; Prochownik EV; Lanza GM; Tomasson MH
Mol Cancer Ther; 2015 Jun; 14(6):1286-1294. PubMed ID: 25824336
[TBL] [Abstract][Full Text] [Related]
3. Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer.
Esser AK; Ross MH; Fontana F; Su X; Gabay A; Fox GC; Xu Y; Xiang J; Schmieder AH; Yang X; Cui G; Scott M; Achilefu S; Chauhan J; Fletcher S; Lanza GM; Weilbaecher KN
Theranostics; 2020; 10(17):7510-7526. PubMed ID: 32685002
[TBL] [Abstract][Full Text] [Related]
4. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.
Huang MJ; Cheng YC; Liu CR; Lin S; Liu HE
Exp Hematol; 2006 Nov; 34(11):1480-9. PubMed ID: 17046567
[TBL] [Abstract][Full Text] [Related]
5. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization.
Clausen DM; Guo J; Parise RA; Beumer JH; Egorin MJ; Lazo JS; Prochownik EV; Eiseman JL
J Pharmacol Exp Ther; 2010 Dec; 335(3):715-27. PubMed ID: 20801893
[TBL] [Abstract][Full Text] [Related]
6. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
[TBL] [Abstract][Full Text] [Related]
7. In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential.
Raffeiner P; Röck R; Schraffl A; Hartl M; Hart JR; Janda KD; Vogt PK; Stefan E; Bister K
Oncotarget; 2014 Oct; 5(19):8869-78. PubMed ID: 25326649
[TBL] [Abstract][Full Text] [Related]
8. Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.
Wang H; Teriete P; Hu A; Raveendra-Panickar D; Pendelton K; Lazo JS; Eiseman J; Holien T; Misund K; Oliynyk G; Arsenian-Henriksson M; Cosford ND; Sundan A; Prochownik EV
Oncotarget; 2015 Oct; 6(32):32380-95. PubMed ID: 26474287
[TBL] [Abstract][Full Text] [Related]
9. Addiction to c-MYC in multiple myeloma.
Holien T; Våtsveen TK; Hella H; Waage A; Sundan A
Blood; 2012 Sep; 120(12):2450-3. PubMed ID: 22806891
[TBL] [Abstract][Full Text] [Related]
10. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
Kim J; Roh M; Abdulkadir SA
BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
[TBL] [Abstract][Full Text] [Related]
11. MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination.
Wu X; Nelson M; Basu M; Srinivasan P; Lazarski C; Zhang P; Zheng P; Sandler AD
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757986
[TBL] [Abstract][Full Text] [Related]
12. Fumagillin prodrug nanotherapy suppresses macrophage inflammatory response via endothelial nitric oxide.
Zhou HF; Yan H; Hu Y; Springer LE; Yang X; Wickline SA; Pan D; Lanza GM; Pham CT
ACS Nano; 2014 Jul; 8(7):7305-17. PubMed ID: 24941020
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug.
Pan D; Sanyal N; Schmieder AH; Senpan A; Kim B; Yang X; Hu G; Allen JS; Gross RW; Wickline SA; Lanza GM
Nanomedicine (Lond); 2012 Oct; 7(10):1507-19. PubMed ID: 22709347
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells.
Wang J; Ma X; Jones HM; Chan LL; Song F; Zhang W; Bae-Jump VL; Zhou C
J Transl Med; 2014 Aug; 12():226. PubMed ID: 25143136
[TBL] [Abstract][Full Text] [Related]
16. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
17. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells.
Zirath H; Frenzel A; Oliynyk G; Segerström L; Westermark UK; Larsson K; Munksgaard Persson M; Hultenby K; Lehtiö J; Einvik C; Påhlman S; Kogner P; Jakobsson PJ; Henriksson MA
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):10258-63. PubMed ID: 23733953
[TBL] [Abstract][Full Text] [Related]
18. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin.
Pastorino F; Mumbengegwi DR; Ribatti D; Ponzoni M; Allen TM
J Control Release; 2008 Feb; 126(1):85-94. PubMed ID: 18166243
[TBL] [Abstract][Full Text] [Related]
19. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy.
Savino M; Annibali D; Carucci N; Favuzzi E; Cole MD; Evan GI; Soucek L; Nasi S
PLoS One; 2011; 6(7):e22284. PubMed ID: 21811581
[TBL] [Abstract][Full Text] [Related]
20. Reversible linkage of two distinct small molecule inhibitors of Myc generates a dimeric inhibitor with improved potency that is active in myc over-expressing cancer cell lines.
Wanner J; Romashko D; Werner DS; May EW; Peng Y; Schulz R; Foreman KW; Russo S; Arnold LD; Pingle M; Bergstrom DE; Barany F; Thomson S
PLoS One; 2015; 10(4):e0121793. PubMed ID: 25875098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
